New drugs can effectively treat blindness: inhibit abnormal blood vessel growth April 17, 2019 Source: Chinese Journal of Science and Technology In a recent study of laboratory mice, US scientists found that a test drug that treated vision loss may be twice as effective. New research shows that this compound, called AXT107, prevents visual obstructive fluids from leaking abnormal blood vessels in the eye. Previous studies have shown that this compound acts to inhibit abnormal blood vessel growth in animal studies of blinding disease, diabetic macular edema, and wet age-related macular degeneration. In the United States, diabetic macular edema and age-related macular degeneration are major causes of vision loss. About 750,000 Americans under the age of 40 have diabetic macular edema, and more than 1.6 million Americans under the age of 50 have wet age-related macular degeneration. If left untreated, both of these diseases eventually lead to blindness. Current drugs retain residual visual acuity primarily by inhibiting abnormal blood vessel growth. The corresponding standard of care is to inhibit new blood vessel growth by direct intraocular injection every month, and the resulting frequent visits may burden the patient. “Based on our findings, we can not only better understand how this potential therapeutic drug can prevent disease progression, but also further determine whether the drug can surpass current use to treat such vision loss in terms of speed, effectiveness and duration of action. Drugs in the patient population," said Aleksander Popel, professor of biomedical engineering at Johns Hopkins University School of Medicine. The researchers reported the results of this research in the recently published Journal of Clinical Investigation. If the eye is healthy, the cells that make up the blood vessels bind together through the proteins on their surface, and these proteins are introduced into place by another protein called Tie2. These proteins are tightly packed together, allowing the cells to act like a Velcro with their neighboring cells, forming a fluid-tight connection between the vascular wall cells. For diabetic macular edema, Tie2 protein is dispersed between cells and can no longer maintain a fluid-tight barrier between the inside and outside of the blood vessel. Due to the formation of gaps between the cells, the liquid can penetrate into the surrounding tissue. To understand how the drug enhances these connections, the researchers designed a series of experiments to explore how AXT107 affects the control of Tie2 and nylon-like proteins. The researchers used laboratory-cultured human vascular cells to simulate cells with wet macular degeneration. After injecting AXT107 into these cells, they found that AXT107 triggered a series of cellular protein changes. By using a technique to measure protein changes, the researchers found that Tie2 protein migrates throughout the cell. The cluster of Tie2 proteins will gradually accumulate in contact with adjacent cells, and then begin to re-establish connections with other vascular cells. The cell edges change from serrated to smooth and continuous so that one cell can better fit another. "It's like pulling them up with a zipper," Popel said. The researchers used fluorescent dyes to observe the ocular blood vessels of normal mice and mice genetically engineered to mimic human macular degeneration. In healthy mice, they observed a clear edge of the luminescence vessel and a small amount of extravascular fluorescence. However, in macular degeneration mice, the luminescent liquid flows through the blood vessels, blurring the barrier between the blood vessels and surrounding tissues. The researchers treated the leaky blood vessels in mice - injecting the AXT107 peptide into the animal's eye. After 4 days, the amount of fluorochrome dye leakage in the mice treated with AXT107 was approximately half that of the animals injected with the drug-free saline. The above results indicate that AXT107 can inhibit vascular leakage and prevent visual obstructive fluid from penetrating into surrounding tissues. Popel said that the previous AXT107 animal model study showed that the drug can form a small transparent gel of sustained-release drug in the eye, so it lasts longer than the existing treatment. If it proves to be effective for people, it may mean that the patient only needs to take one or two eye injections per year instead of receiving monthly injections according to the current standard care regimen. "In addition to improving patient response, the benefits of AXT107 are also reflected in the longer duration, the lower the frequency of dosing, and the lower the patient's therapeutic burden," Popel said. Next, the researchers plan to conduct clinical trials in patients with diabetic macular edema next year to test the safety and efficacy of AXT107 peptide . (Zhao Xixi) 10000Hz High Frequency LiDAR Module 10000 Hz is one of our 2021 new solutions products,which can be widely used in drone postioning, car anti-collision, intelligent traffic monitoring etc. with high accuracy. We support customized service of different frequency(100hz,200hz,300hz,400hz,1000hz,5000hz,10000hz etc.), you can choose the suitable design. And the LiDAR module is a small size with 43*35*21mm, customers can be integrated to their measure device easily. If you meed any documents(PDF files etc.) of JRT high frequency LiDAR distance sensor, please contact us now. 10000Hz High Frequency LiDAR Module,LiDAR,High Frequency LiDAR Module,10000Hz LiDAR Module Chengdu JRT Meter Technology Co., Ltd , https://www.rangesensors.com
Some key features may help:
Accuracy: ±3~5cm(<50m) /±1%(>50m)
Range: 0.1-200m
Resolution: 1cm
Frequency: 100/200/400/1k/5k/10khz
Laser type: 905nm,Class I
Size: 43*35*21mm
Weight: 20g
Input voltage: 8-36V